In this study, the patients will randomly receive either Promacta/Vidaza combination every 28 days for at least 6 cycles, or placebo plus Vidaza. The primary endpoint of the study is to compare the ...
We note that Promacta is currently approved for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenia purpura (:ITP). The drug is also approved for the treatment of ...
Promacta (eltrombopag) can cause side effects ranging from mild issues like nausea and fatigue to more serious complications, such as cataracts. Promacta has boxed warnings about the potential for ...
First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...
The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...
GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. The British pharmaceutical giant, which has its U.S. headquarters in Research ...
Promacta (eltrombopag) is a brand-name drug prescribed for certain blood conditions. Promacta has interactions with some supplements and drugs. Examples include some antacids and certain statins. An ...
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...
PHILADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK)announced positive safety and efficacy results from RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag), a Phase III study of ...
CHICAGO, May 30 (Reuters) - An expert advisory panel to the U.S. Food and Drug Administration said on Friday that current clinical data supports short-term use of GlaxoSmithKline Plc's experimental ...
Basel, January 4, 2018 - Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Promacta ® (eltrombopag) for use in combination with ...
Novartis’ Promacta has been given Breakthrough Therapy Designation by the FDA for previously untreated patients with severe aplastic anaemia (SAA). The Swiss pharma giant has been uniquely successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results